Innate immune responses to infection are induced in part by Toll-like receptors (TLRs), which belong to the pattern recognition receptor family. To date, 10 human and 12 mouse TLRs are known, each of which binds specific ligands. TLR4 recognises lipopolysaccharide (LPS) from Gram-negative bacteria and signals in combination with other co-receptors to activate the NF-kB transcription factors^[@R1]^. TLR4 is involved in diseases such as sepsis and chronic inflammatory disorders^[@R2],[@R3]^. TLR4 signalling in tumour cells is associated with suppression of immune surveillance, proliferation, inflammatory cytokine production, and invasive migration^[@R4]--[@R8]^. Therefore, understanding the regulation of TLR4 expression and signalling may be important for the management of these conditions.

C/EBPδ is an inflammatory response gene^[@R9]^. C/EBPδ amplifies LPS signalling, and it is essential for the expression of many LPS-induced genes and the clearance of Gram-negative bacterial infection^[@R10]^. *Cebpd* deficiency partly protects mice from LPS-induced mortality and autoimmune encephalomyelitis, suggesting that C/EBP™ has a role in the progression of systemic inflammatory diseases such as sepsis and multiple sclerosis^[@R11],[@R12]^.

We reported that C/EBPδ directly inhibits the expression of the F-box and WD repeat domain containing protein 7 alpha (FBXW7α) in mammary tumour cells^[@R13]^. The *Fbxw7* gene encodes three protein isoforms, of which the alpha isoform is the most abundantly expressed^[@R14]^. FBXW7 functions as the substrate-recognition subunit of SCF-type ubiquitin ligase complexes. FBXW7α targets various mammalian oncoproteins for degradation, including c-myc, cyclin E, mTOR, c-jun and Notch^[@R14],[@R15]^. We also showed that hypoxia-induced C/EBPδ inhibited the expression of FBXW7α, resulting in elevated levels of mTOR and consequently hypoxia-inducible factor 1 alpha (HIF-1α)^[@R13]^. HIF-1α is a subunit of the HIF-1 transcription factor complex and is necessary for cellular adaptation to hypoxia. HIF-1 target genes promote angiogenesis and the metabolic switch to glycolysis, which augments survival under hypoxia^[@R16]^. In agreement with the role of hypoxia and HIF-1α in tumour metastasis^[@R17],[@R18]^, loss of *Cebpd* results in reduced metastatic progression of MMTV-Neu-induced mammary tumours^[@R13]^. MMTV-Neu transgenic mice express the rat tyrosine kinase receptor Neu (ERBB2/HER2) specifically in mammary epithelial cells, mimicking the overexpression of ERBB2 observed in 30% of human breast cancers^[@R19]^. Although*Cebpd*-deficient MMTV-Neu-transgenic mice are 50% less likely than wild-type mice to develop metastases, these mice also exhibit a 50% increased tumour multiplicity compared to controls^[@R13]^; these observations are in agreement with other tumour-suppressor like activities of C/EBPδ, such as suppression of cyclin D1 expression^[@R13],[@R20],[@R21]^.

HIF-1α also promotes macrophage activation and inflammatory responses, as does the FBXW7α target Notch^[@R22],[@R23]^. However, the role of FBXW7α in inflammatory signalling has not been addressed. Because C/EBPδ augments HIF-1α expression in tumour cells^[@R13]^, and both C/EBPδ and HIF-1α are known to mediate inflammatory responses, we hypothesised that the C/EBPδ-FBXW7-HIF-1 pathway played a role in macrophage activation. Here, we show that C/EBPδ augments HIF-1α expression and pro-inflammatory signalling in activated macrophages through the inhibition of FBXW7α expression. We also found that C/EBPδ acts upstream of LPS signalling by directly activating *Tlr4* gene expression. In addition, we identified a negative feedback loop where FBXW7α downregulates C/EBPδ that is phosphorylated by GSK-3β. These results identify a novel role for FBXW7α as a suppressor of inflammatory gene expression.

RESULTS {#S1}
=======

LPS and C/EBPδ inhibit FBXW7α expression in macrophages {#S2}
-------------------------------------------------------

We previously reported that C/EBPδ directly inhibits *Fbxw7α* gene expression in tumour cells, which in turn augments HIF-1α expression^[@R13]^. To investigate this pathway in macrophages, we first analysed FBXW7 isoform expression. Semi-quantitative analysis suggested that macrophages and mammary tumours expressed only *Fbxw7α* mRNA but not *Fbxw7β* or *Fbxw7γ*, while all three isoforms were detected in mouse embryo fibroblasts ([Fig. 1a](#F1){ref-type="fig"}). In mouse primary peritoneal macrophages (PPMs), basal levels of *Fbxw7α* mRNA were higher in *Cebpd^−/−^* (KO) compared to wild-type (WT) macrophages. LPS treatment decreased *Fbxw7α* transcripts in WT but not in KO macrophages ([Fig. 1b](#F1){ref-type="fig"}). The silencing of *CEBPD* by RNAi in U-937 human monocytic cells increased the basal level of *FBXW7* mRNA and abolished its repression upon LPS treatment ([Supplementary Fig. S1a](#SD1){ref-type="supplementary-material"}). Next, we analysed resident peritoneal exudate cells (PECs), which consisted of approximately 67±2.7% macrophages/monocytes, 23±1% lymphoid cells, and 4.9±0.6% neutrophils independent of genotype (mean±S.E.M, n=4 mice). *In vivo* LPS treatment (6 h) reduced FBXW7α protein levels in WT PECs but not in *Cebpd^−/−^* cells, while C/EBPδ expression was induced by this treatment in WT PECs ([Supplementary Fig. S1b](#SD1){ref-type="supplementary-material"}). Furthermore, the higher levels of basal FBXW7α that were observed in *Cebpd^−/−^* PECs ([Supplementary Fig. S1b, c](#SD1){ref-type="supplementary-material"}) were correlated with reduced levels of its targets mTOR and Aurora A and reduced phosphorylation of AKT, S6K1 and GSK-3β ([Supplementary Fig. S1c](#SD1){ref-type="supplementary-material"}). Taken together, these data show that macrophages express FBXW7α and that FBXW7α expression is downregulated by C/EBPδ and LPS.

C/EBPδ and FBXW7α control HIF-1α expression in monocytes {#S3}
--------------------------------------------------------

LPS and hypoxia cooperatively induce HIF-1α expression in macrophages^[@R24]^, and we confirmed these results in ANA-1 mouse macrophages ([Supplementary Fig. S1d](#SD1){ref-type="supplementary-material"}). Under these conditions, primary human monocytes treated with *CEBPD* RNAi had increased FBXW7α expression and reduced HIF-1α accumulation ([Fig. 1c](#F1){ref-type="fig"}). As expected^[@R13]^, *CEBPD* depletion also increased *FBXW7α* mRNA levels ([Fig. 1d](#F1){ref-type="fig"}). Interestingly, FBXW7α depletion increased the levels of C/EBPδ and HIF-1α protein ([Fig. 1c](#F1){ref-type="fig"}) and of *CEBPD* mRNA ([Fig. 1d](#F1){ref-type="fig"}), demonstrating that FBXW7α suppresses C/EBPδ expression. In *Cebpd^−/−^* PPMs, HIF-1α accumulation could be rescued by knockdown of the elevated FBXW7α ([Fig. 1e](#F1){ref-type="fig"}). These results demonstrate that C/EBPδ promotes HIF-1α expression in activated macrophages through the inhibition of FBXW7α expression, as previously reported for mammary tumour cells^[@R13]^.

HIF-1 is critical for hypoxia-induced glycolysis in macrophages^[@R22]^. Therefore, we examined if reduced HIF-1α expression in *Cebpd* null PECs affected their glycolytic activity and activation. Under inflammatory conditions (LPS+1% O~2~), *Cebpd* null PECs exhibited reduced hallmarks of the glycolytic switch, such as glucose consumption and lactate generation ([Supplementary Fig. S1e](#SD1){ref-type="supplementary-material"}). In agreement with these data, ATP production and the survival of *Cebpd* null peritoneal cells were reduced under these conditions ([Supplementary Fig. S1f--g](#SD1){ref-type="supplementary-material"}). Furthermore, *Cebpd*-deficient peritoneal macrophages exhibited limited induction of pro-inflammatory genes, such as *Mmp9, Cxcr4, Vegfc* and *Il6*, after stimulation with LPS+1% O~2~ ([Supplementary Fig. S1h](#SD1){ref-type="supplementary-material"}). These genes are known HIF-1 targets^[@R18]^; *Il6* and *Cxcr4* are also direct targets of C/EBPδ^[@R10],[@R13]^. Collectively, these findings show that C/EBPδ supports HIF-1-mediated inflammatory responses.

Importantly, there was no difference in the number of PECs isolated from *Cebpd^−/−^* mice compared with the controls. However, there was a small but significant decrease in the number of PPMs isolated from *Cebpd^−/−^* mice after elicitation, and there was a significant decrease in the recruitment of peritoneal cells upon LPS treatment *in vivo* ([Supplementary Fig. S2a, b](#SD1){ref-type="supplementary-material"}). An analysis of baseline myeloid haematopoiesis suggests that myeloid development is normal in *Cebpd^−/−^* mice (see [Supplementary Note 1 and Fig. S2c--j](#SD1){ref-type="supplementary-material"}). Thus, we conclude that the functional differences detected in the macrophages from *Cebpd^−/−^* mice are not due to developmental defects.

FBXW7α targets C/EBPδ for degradation {#S4}
-------------------------------------

FBXW7α is not a transcription factor. Therefore, its downregulation of *Cebpd* mRNA levels must be through indirect mechanisms. Because C/EBPδ can activate its own promoter^[@R10]^ and has a degron-like sequence commonly found in FBXW7 substrates^[@R14],[@R15]^, we investigated whether FBXW7α regulated C/EBPδ expression at the protein level. Pulse-chase analysis ([Fig. 2a](#F2){ref-type="fig"}) and cycloheximide-chase experiments ([Supplementary Fig. S3a](#SD1){ref-type="supplementary-material"}) showed that the half-life of C/EBPδ protein increased significantly when *Fbxw7α* was silenced in RAW 264.7 macrophages. Furthermore, inhibition of the proteasome by MG132 increased the basal expression of C/EBPδ and revealed its polyubiquitination, which was significantly reduced upon *Fbxw7α* silencing ([Fig. 2b](#F2){ref-type="fig"} and [Supplementary Fig. S3b](#SD1){ref-type="supplementary-material"}). In *Fbxw7α*-silenced cells, MG132 did not further increase C/EBPδ protein levels. In contrast, ectopic FBXW7α^[@R25]^ further decreased the half-life of C/EBPδ and increased its polyubiquitination ([Supplementary Fig. S3c, d](#SD1){ref-type="supplementary-material"}). Co-immunoprecipitation assays showed that ectopic and endogenous C/EBPδ physically interacted with FBXW7α ([Supplementary Fig. S3e](#SD1){ref-type="supplementary-material"}). These results indicate that FBXW7α is required for the ubiquitination and degradation of C/EBPδ in RAW 264.7 macrophages. Accordingly, C/EBPδ binding to its own promoter increased when *Fbxw7α* was silenced ([Supplementary Fig. S3f](#SD1){ref-type="supplementary-material"}). Collectively, these data demonstrate a negative feedback loop from FBXW7α to C/EBPδ.

FBXW7-substrate interaction requires a phospho-degron motif, which is also present in C/EBPδ ([Fig. 2c](#F2){ref-type="fig"}). To investigate the role of this motif, we mutated the potential phospho-acceptor residues serine and threonine to alanine (TTS/AAA). [Figure 2d](#F2){ref-type="fig"} shows that FBXW7α decreased the steady-state levels of the ectopic wild-type C/EBPδ but not the TTS/AAA mutant. Co-immunoprecipitation assays revealed that the degron motif of C/EBPδ was necessary for its interaction with FBXW7α ([Fig. 2e](#F2){ref-type="fig"}). Indeed, FBXW7α mediated the polyubiquitination of WT- but not TTS/AAA-C/EBP™ *in vitro* ([Fig. 2f](#F2){ref-type="fig"}), and the degron motif was required for polyubiquitination *in vivo* ([Fig. 2g](#F2){ref-type="fig"}). Next, we generated a TTS/DDD mutation to mimic its phosphorylation, and we confirmed that this protein interacted with FBXW7α ([Fig. 2h](#F2){ref-type="fig"}). The half-life of TTS/DDD-C/EBPδ was significantly reduced compared to the stabilisation observed with the TTS/AAA mutation ([Fig. 2i](#F2){ref-type="fig"}). In the presence of MG132, WT- and TTS/DDD-C/EBPδ were expressed at similar steady-state levels; these findings corroborated the notion that the low levels of TTS/DDD-C/EBPδ were due to degradation ([Fig. 2j](#F2){ref-type="fig"}). Collectively, these data show that degron-phosphorylation regulates the stability of C/EBPδ.

GSK-3β regulates C/EBPδ protein stability {#S5}
-----------------------------------------

The serine/threonine kinase GSK-3β is responsible for the phosphorylation of most FBXW7α substrates^[@R14]^. Indeed, phospho-threonine could be detected on WT-C/EBPδ expressed in RAW 264.7 cells, but this phosphorylation was significantly reduced by the GSK-3β inhibitor CHIR or the TTS/AAA mutation ([Fig. 3a](#F3){ref-type="fig"}). Consistent with this result, the GSK-3β inhibitors CHIR or BIO increased the expression of C/EBPδ in PPMs and RAW 264.7 cells ([Fig. 3b](#F3){ref-type="fig"}). In contrast, the expression of TTS/DDD-C/EBPδ was not increased by CHIR ([Fig. 3c](#F3){ref-type="fig"}). These results suggest a role for the GSK-3β pathway in the regulation of C/EBPδ expression. Indeed, *in vitro* kinase assays with recombinant activated GSK-3β confirmed that GSK-3β directly phosphorylated C/EBPδ ([Fig. 3d](#F3){ref-type="fig"}). The TTS/AAA mutation significantly reduced C/EBPδ phosphorylation, and phospho-peptide analysis confirmed that GSK-3β targets T156 of the degron ([Fig. 3d](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Phosphorylation at S160 was also detected but to a much lesser extent. In addition, T49 was phosphorylated by GSK-3β *in vitro* on both WT- and TTS/AAA-C/EBPδ. This residue is not conserved across species and its role, if any, remains to be determined.

Our results show that GSK-3β phosphorylation attenuates C/EBPδ levels in untreated macrophages. Next, we investigated the role of this pathway in activated macrophages. LPS signalling inhibits GSK-3β through the PI3K/AKT pathway^[@R26]^. LPS reduced threonine-phosphorylation of C/EBPδ, which was consistent with an increase in the inhibitory Ser9-phosphorylation on GSK-3β ([Fig. 3e](#F3){ref-type="fig"}) and in the half-life of C/EBPδ ([Fig. 3f](#F3){ref-type="fig"}). Furthermore, ectopic active GSK-3β-S9A^[@R27]^ ([Fig. 3g](#F3){ref-type="fig"}) or pharmacological inhibition of PI3K/AKT reduced LPS-induced C/EBPδ expression ([Fig. 3h](#F3){ref-type="fig"}). These data show that LPS activates C/EBPδ expression at least in part by inhibition of the GSK-3β/FBXW7α pathway.

FBXW7α regulates TLR4 expression through C/EBPδ {#S6}
-----------------------------------------------

Because FBXW7α targeted C/EBPδ for degradation, FBXW7α could have a role in attenuating pro-inflammatory signalling. To test this hypothesis, we expressed FBXW7α^[@R25]^ in PPMs to mimic the elevated levels of FBXW7α in *Cebpd* null cells ([Supplementary Fig. S4a](#SD1){ref-type="supplementary-material"}). FBXW7α suppressed all tested responses of PPMs to LPS, such as the expression of iNOS, C/EBPδ, p65, Notch-intracellular-domain (NICD) and COX-2 and the phosphorylation of ERK1/2 and STAT3 ([Fig. 4a](#F4){ref-type="fig"}). Similar data were obtained with RAW 264.7 macrophages ([Supplementary Fig. S4b](#SD1){ref-type="supplementary-material"}). Furthermore, the transcript levels of *Nos2, Cebpd, Il6, Vegfc*, and *Mmp9* were significantly reduced by ectopic FBXW7α in PPMs ([Fig. 4b](#F4){ref-type="fig"}), as was NO production and the glycolytic switch in response to LPS+1% O~2~ ([Supplementary Fig. S4c, d](#SD1){ref-type="supplementary-material"}). These data are reminiscent of the phenotype of *Cebpd* null cells, which express elevated levels of FBXW7α. The profound suppression of LPS-responses by ectopic FBXW7α suggested that upstream elements in the LPS signalling pathway were downregulated by FBXW7α. Intracellular LPS signalling is initiated by TLR4^[@R1]^. Indeed, ectopic FBXW7α reduced expression of TLR4 along with C/EBPδ in PPMs ([Fig. 4c](#F4){ref-type="fig"}), while RNAi against *Fbxw7α* increased the basal and LPS-induced levels of TLR4 and C/EBPδ ([Fig. 4d](#F4){ref-type="fig"}). In addition, several pro-inflammatory markers, such as NICD, iNOS and p65, were induced by *Fbxw7α*-silencing alone ([Fig. 4d](#F4){ref-type="fig"}). These data prompted the hypothesis that FBXW7α regulates TLR4 expression through C/EBPδ. The depletion of C/EBPδ prevented the upregulation of TLR4 in response to *Fbxw7α* silencing ([Fig. 4e](#F4){ref-type="fig"}), demonstrating that C/EBPδ mediates TLR4 upregulation. Even basal expression of TLR4 depended on C/EBPδ. Lastly, co-expression of degradation-resistant TTS/AAA-C/EBPδ with FBXW7α rescued TLR4 expression in RAW 264.7 macrophages, demonstrating that FBXW7α downregulates TLR4 through the inhibition of C/EBPδ expression ([Fig. 4f](#F4){ref-type="fig"}).

FBXW7α suppresses inflammatory signaling {#S7}
----------------------------------------

Increased basal levels of TLR4 and C/EBPδ protein due to RNAi against *Fbxw7α* were also observed in RAW 264.7 macrophages, along with increased transcript levels of the pro-inflammatory genes *Cebpd, Tlr4, Tnfa, Il6, Nos2* and*Mmp9* in PPMs ([Supplementary Fig. S5a, b](#SD1){ref-type="supplementary-material"}). Taking this approach further, we silenced *Fbxw7α in vivo* by intraperitoneal injection of siRNA. *In vivo* RNAi can cause non-specific effects that include activation of the immune system^[@R28]^. Indeed, control siRNAs led to a modest increase of C/EBPδ expression in PECs compared to vehicle treatment ([Supplementary Fig. S5c](#SD1){ref-type="supplementary-material"}). In comparison, two *Fbxw7α* RNAi oligos caused a greater increase in both C/EBPδ and TLR4 protein levels. Following this pilot experiment, *Ctrl1* and *Fbxw7α1* siRNA were used for subsequent analyses. Peritoneal cells that were isolated two days after the injection of *Fbxw7α* siRNA exhibited reduced FBXW7α levels and higher basal expression of C/EBPδ, TLR4, NICD, p65, and iNOS protein compared with control siRNA ([Fig. 4g](#F4){ref-type="fig"}). In addition, transcripts for *Cebpd, Nos2* and*Il6* were induced ([Supplementary Fig. S5d](#SD1){ref-type="supplementary-material"}). More cells were recovered from *Fbxw7α*-siRNA treated mice, indicating the activation of recruitment pathways ([Supplementary Fig. S5e](#SD1){ref-type="supplementary-material"}). However, the ratios of different PECs was not altered ([Supplementary Fig. S5f](#SD1){ref-type="supplementary-material"}). Furthermore, *Fbxw7α* siRNA resulted in detectable levels of plasma IL-6 in otherwise untreated mice and in increased IL-6 concentrations in LPS-treated mice ([Fig. 4h](#F4){ref-type="fig"}). These data show that endogenous FBXW7α is necessary to prevent pro-inflammatory gene expression. RNAi depletion of FBXW7α in PPMs sensitised the cells, such that 1 ng/ml LPS elicited a response that was comparable to 10--100 ng in control cells, as measured by the expression of C/EBPδ and p65 and the phosphorylation of ERK and p38 MAP kinase ([Fig. 4i](#F4){ref-type="fig"}). Note that *Fbxw7* RNAi increased the basal TLR4 protein levels to LPS-induced levels at this 4 h time point. Taken together, these data show that FBXW7α attenuates the LPS response through inhibition of C/EBPδ and TLR4 expression and that FBXW7α-depletion alone is sufficient to activate inflammatory signalling.

TLR4 is a direct transcriptional target of C/EBPδ {#S8}
-------------------------------------------------

Because C/EBPδ promoted TLR4 protein expression, we next addressed the mechanism underlying this regulation. The loss of C/EBPδ in KO PECs or RNAi-depleted RAW 264.7 macrophages reduced *Tlr4* mRNA levels ([Fig. 5a](#F5){ref-type="fig"}). Similarly, overexpression of FBXW7α suppressed *Tlr4* mRNA levels ([Fig. 5b](#F5){ref-type="fig"}), which was consistent with the induced *Tlr4* mRNA levels upon *Fbxw7α* silencing ([Supplementary Fig. S5b](#SD1){ref-type="supplementary-material"}). Interestingly, the expression of *Tlr2, Tlr4*, and*Tlrs 5--9* was also reduced in *Cebpd*-deficient PPMs, while the expression of *Tlr1* and*Tlr3* was increased ([Supplementary Fig. S5g](#SD1){ref-type="supplementary-material"}). These data implicate C/EBPδ in the regulation of most *Tlr* genes. Because of our aforementioned data, we focused our subsequent analyses on TLR4. Inspection of the *Tlr4* promoter sequence revealed putative C/EBP binding sites within 200 bp upstream of the transcription start site ([Fig. 5c](#F5){ref-type="fig"}). ChIP analysis of PPMs demonstrated the binding of C/EBPδ to the proximal *Tlr4* promoter region but not to a distal promoter region, where there were no putative binding sites ([Fig. 5c](#F5){ref-type="fig"}). Consistent with these data, *Cebpd* RNAi or FBXW7α overexpression both reduced the activity of a *Tlr4* promoter-luciferase reporter construct ([Fig. 5d](#F5){ref-type="fig"}). Next, we assessed the effect of TLR4 reconstitution in *Cebpd* null PPMs ([Fig. 5e](#F5){ref-type="fig"}). Overexpression of TLR4^[@R29]^ in WT PPMs had no significant effect on the LPS-induced expression of *Nos2* and*Il6*. In *Cebpd*-deficient macrophages, however, ectopic TLR4 significantly enhanced LPS-induction of *Nos2* and *Il6* transcripts ([Fig. 5f](#F5){ref-type="fig"}). C/EBPδ binds the *Il6* promoter^[@R10]^ and may regulate the *iNOS* promoter directly^[@R30]^. Our data show that the impaired LPS response of *Il6* and *Nos2* in *Cebpd* null macrophages is in part due to reduced TLR4 levels, and it is less due to the role of C/EBPδ as a downstream effector of TLR4. The role of basal C/EBPδ expression was further supported by an analysis of early LPS signalling events. The accumulation of p65 and the phosphorylation of ERK, p38 and JNK kinases in response to LPS were attenuated in *Cebpd* null PPMs within 30--60 min of treatment ([Fig. 5g](#F5){ref-type="fig"}). In summary, these results show that C/EBPδ also functions upstream of LPS signalling through activation of *Tlr4* gene expression.

C/EBPδ augments inflammatory signalling in tumours {#S9}
--------------------------------------------------

TLR4 is expressed in both macrophages and tumour cells^[@R4]^. Proteins such as HMGB1 and S100A8 act as ligands that activate TLR4 signalling, and these ligands are important in tissue repair, inflammatory diseases, and cancer^[@R3],[@R31],[@R32]^. Inflammation-associated gene expression is strongly correlated with tumour malignancy^[@R33]^. Given that C/EBPδ promotes metastatic progression of MMTV-Neu mammary tumours^[@R13]^, we investigated whether C/EBPδ modulates TLR4 expression in tumour cells. Stable depletion of C/EBPδ in a mouse mammary tumour cell line or in human MCF-7 breast tumour cells reduced TLR4 protein expression and induced FBXW7α levels ([Fig. 6a](#F6){ref-type="fig"}). Analyses of MMTV-Neu tumour tissue confirmed the reduced *Tlr4* mRNA, increased *Fbxw7* mRNA, and, on average, lower TLR4 protein levels in *Cebpd^−/−^* tumours compared with WT ([Fig. 6b](#F6){ref-type="fig"}). In addition, iNOS protein expression ([Fig. 6b](#F6){ref-type="fig"}) and *Il6, Nos2, Arg1*, and*Tnfa* transcript levels were lower in *Cebpd^−/−^* tumours ([Fig. 6c](#F6){ref-type="fig"}). Interestingly, the transcript levels of *Il10* and *Il13*, which are expressed in cells including alternatively activated macrophages and T cells, were significantly higher in *Cebpd^−/−^* tumours ([Fig. 6c](#F6){ref-type="fig"}). The inverse correlation of *Cebpd* and *Il10* expression *in vivo* is consistent with a previous report on C/EBPδ functions in dendritic cells^[@R12]^.

We also examined the expression of chemokines and chemokine receptors, which play an important role in breast tumour progression and metastasis^[@R34]^. C*ebpd* KO tumours exhibited significantly reduced expression of the metastasis-promoting gene *Cxcr4*, which was consistent with our previous report that C/EBPδ directly regulates *Cxcr4* in cultured mammary tumour cells^[@R5]^. In contrast, C/EBPδ-null tumours exhibited increased expression of *Ccl3* and *Ccl5*, which augment T-cell mediated anti-immune responses^[@R35]^ ([Supplementary Fig. S6](#SD1){ref-type="supplementary-material"}). Of these genes, the *Ccl3* gene promoter is directly activated by C/EBPδ after LPS induction^[@R4]^. Collectively, these data show that the loss of C/EBPδ leads to complex alterations of pro-and anti-inflammatory genes in mammary tumour tissue and that this complexity may be due to its multifaceted roles in macrophages and mammary epithelial cells.

Macrophages and tumour cells engage in crosstalk, and a metastasis-promoting paracrine loop has been described with breast carcinoma cells producing colony stimulating growth factor-1 (CSF-1) and macrophages expressing epidermal growth factor (EGF)^[@R36]^. We found that both *Csf1* and *Egf* expressions were significantly reduced in *Cebpd* null MMTV-Neu mammary tumours ([Fig. 6d](#F6){ref-type="fig"}). Though further analyses will be required to dissect the contribution of different cell types to these observations, the results are likely due to C/EBPδ action in both the immune cells and tumour cells. In summary, these data show that C/EBPδ activity profoundly affects the expression of proteins that are modulators of the immune system, which collectively creates a largely pro-inflammatory microenvironment in mammary tumours.

DISCUSSION {#S10}
==========

In this study, we identified a positive feedback loop between C/EBPδ and TLR4 and a negative feedback loop between C/EBPδ and FBXW7α, which together modulate TLR4 signalling and pro-inflammatory gene expression ([Fig. 7](#F7){ref-type="fig"}). Phosphorylation of C/EBPδ by GSK-3β is required for its degradation by FBXW7α. Therefore, inhibition of GSK-3β by LPS stabilises C/EBPδ. Identification of TLR4 as a direct transcriptional target of C/EBPδ renders C/EBPδ a pro-inflammatory factor upstream of TLR4 in addition to its functions downstream.

Macrophages can be activated by several pathways, and C/EBPδ together with C/EBPβ also participates in Fcγ receptor-mediated inflammatory cytokine and chemokine production and in IgG IC-stimulation of macrophages^[@R37]^. In addition to our data, the regulation of *Tlr8* expression by C/EBPδ as well as its binding to the *Tlr6* gene promoter have been reported^[@R10],[@R38]^. A critical role of C/EBPδ in LPS responses has previously been shown *in vitro* and *in vivo*. *Cebpd* null mice are hypersensitive to persistent bacterial infection^[@R10]^ and hyposensitive to septic shock after sensitisation^[@R11]^. Both phenotypes were attributed to the role of C/EBPδ as an inflammatory response gene and regulator of target genes such as *Il6*. Furthermore, the role of C/EBPδ in amplifying LPS signalling has been described^[@R39]^. It should be noted that one study reported that C/EBPδ is dispensable for LPS-induced *Il6* expression^[@R40]^. It remains to be determined which experimental details are responsible for the difference in results.

Our findings place C/EBPδ upstream of LPS signalling for expression of the TLR4 receptor. The loss of C/EBPδ does not abolish *Tlr4* expression entirely, which explains why LPS responses are not completely impaired. Interestingly, our data from reconstituting *Cebpd^−/−^* cells with ectopic TLR4 suggest that the precise role of C/EBPδ downstream of TLR signalling should be re-evaluated in light of its role in regulating TLR4 expression. Low dose LPS specifically induces C/EBPδ expression rather than NF-kB^[@R41]^, supporting the notion that C/EBPδ is critical in sensitising cells to LPS.

Our data show that C/EBPδ promotes macrophage activation in part by augmenting HIF-1α expression. Inflamed tissue is hypoxic and HIF-1 mediates hypoxia adaptation by regulating the transcription of many genes associated with angiogenesis, glycolysis, and migration^[@R16]^. C/EBPδ also promotes tumour lymphangiogenesis through HIF-1^[@R42]^. Our results show that macrophage functions that require HIF-1 are blunted in the absence of C/EBPδ because of *Fbxw7α* derepression. HIF-1α expression in the myeloid lineage also promotes the differentiation of myeloid-derived tumour suppressor cells (MDSCs), which contribute to tumour progression^[@R17],[@R18],[@R43]^. This mechanism may underlie the pro-metastatic function of C/EBPδ in addition to the role of this pathway in epithelial-derived tumour cells^[@R13]^.

Interestingly, TLR4 is also a target of HIF-1^[@R44]^; hence, C/EBPδ induces TLR4 expression directly under normoxia and also indirectly through HIF-1 induction under hypoxia. This effect provides an additional positive feedback loop because C/EBPδ is a hypoxia-induced gene that is likely downstream of HIF-1^[@R13],[@R42]^. However, this pro-inflammatory loop requires simultaneous inhibition of FBXW7α expression by C/EBPδ, suggesting that FBXW7α serves as an important brake on inflammatory signalling.

In this study, we found that *Cebpd*-deficient mouse mammary tumour tissues, which exhibit reduced metastatic progression^[@R13]^, express increased FBXW7α and reduced TLR4 levels. The effects of TLR4 signalling on cancer appear complex and may depend not only on the cell type but also on the stage of tumour development^[@R6],[@R7],[@R45]--[@R48]^. In our study, reduced TLR4 expression in *Cebpd* null tumours correlated with mostly reduced pro-inflammatory and increased anti-inflammatory gene expression. This result may be due to the role of C/EBPδ in mammary tumour cells and infiltrating immune cells, direct targeting by C/EBPδ, or indirect downstream effects. Interestingly, reduced innate immune responses in *Cebpd* null mice are also consistent with the increased mammary tumour multiplicity in these mice^[@R13]^. Our data warrant further dissection of the role of C/EBPδ in tumour-associated macrophages and their crosstalk with mammary tumour cells, which will be addressed by conditional gene deletion in future analyses.

From this study, FBXW7α emerged as a potent attenuator of inflammatory signalling. This activity is at least in part due to suppression of C/EBPδ expression at the protein and mRNA levels and is likely to affect not only *Cebpd* but also other genes/proteins that modulate inflammation. Therefore, our data lay the groundwork for further analyses of FBXW7α functions in the modulation of immune cells. We also suggest that the tumour suppressor activity of FBXW7^[@R14]^ could be in part due to its role as an attenuator of pro-inflammatory gene expression. According to the "1000 Genomes" catalogue ([www.1000genomes.org](http://www.1000genomes.org)), the *FBXW7* gene harbours several SNPs, some with possibly deleterious effects on function. We suggest that these SNPs be included in genome-wide association studies of inflammatory diseases. Given the role of FBXW7α as a suppressor of inflammatory signalling (as shown in this study) and as a *bona fide* tumour suppressor^[@R14],[@R15]^, FBXW7α is an unlikely therapeutic target. However, better knowledge of the regulation of its expression and its target proteins may provide new avenues for the management of inflammation-associated diseases.

METHODS {#S11}
=======

Reagents and antibodies {#S12}
-----------------------

Lipopolysaccharide (LPS from *E. coli*; L4524) was purchased from Sigma-Aldrich, St. Louis, MO. CHIR99021 and BIO (6-Bromoindirubin-3'-oxime) were obtained from Stemgent, San Diego, CA. Antibodies were obtained from the following sources: Cell Signaling Technology (pGSK-3β-Ser9, \#9336; pAKT-Ser473, \#4060; pS6K1-Thr389, \#9205; pSTAT3, \#9145; AKT, \#4691; GSK-3β, \#9315; S6K1, \#9202; STAT3, \#4904; Cleaved Notch-1, \#2421S; phospho-p44/42 MAPK-Thr202/Tyr204 (pErk1/2), \#9101; p44/42 MAPK (Erk1/2), \#9102; pp38-Thr180/Tyr182, \#9215S; p38, \#9212; pSAPK/JNK-Thr183/Tyr185, \#4668S; SAPK/JNK, \#9258; phospho-threonine, \#9386S); Abcam (iNOS, \#ab-15323; F4/F80, \#ab-60343-100; Cox-2, \#ab-15191; p65 (RelA); \#ab-16502; FBXW7, ab\#12292); BD Pharmingen (CD11b (M1/70), \#550993; GR1, \#553128; CD16/CD32, \#553142); Novus Biologicals (HIF-1α, \#NB100--449; HIF-1β, \#NB-100--124); Santa Cruz (actin, sc-1616; Ubiquitin, sc-8017); Calbiochem (mTOR, \#OP97); Orbigen (FBXW7alpha, \#PAB-10563); BD Biosciences (Aurora A, \#610938); Imgenex (TLR4, \#IMG-578A); Bethyl Laboratories (H2AX, \#A300-083A); eBioscience (B220, \#RA3-6B2; CD3e, \#500A-2, and isotype controls); Roche (HA, \#11867423001; clone3F10); and Rockland (Tubulin, \#600-401-880). The mouse monoclonal antibody clone L46--743.92.69 (batch BD69319) against C/EBPδ was provided by BD Biosciences Pharmingen as an outcome of an Antibody Co-development Collaboration with the NCI.

For information on plasmids see [Supplementary Methods](#SD1){ref-type="supplementary-material"}.

Mice and isolation of peritoneal cells {#S13}
--------------------------------------

*Cebpd* wild-type and knockout mice^[@R49]^ were of the FVB/N strain background (except for data in [Supplementary Fig. S2](#SD1){ref-type="supplementary-material"}, which are from 129S1 mice) and derived from heterozygous mates. The MMTV-c-Neu tumour model has been described ^[@R13],[@R19]^. The subjects were littermates whenever possible. NCI-Frederick (FNLCR) is accredited by AAALLC International and follows the Public Health Service Policy for the care and use of laboratory animals. All experiments were conducted according to protocols approved by the Institutional Animal Care and Use Committee.

For the isolation of PPMs, mice were injected with 3% Brewer thioglycollate medium^[@R50]^ in the peritoneal cavity. Four days later, mice were euthanised, and 10 ml sterile PBS (Ca^2+^/Mg^2+^-free) was injected into the peritoneal cavity. The resulting peritoneal fluid was collected and centrifuged at 400 × *g* for 10 min at 4°C. The cell pellet was washed once with PBS. Erythrocytes were lysed with sterile water, and the final pellet was suspended in 1:1 DMEM/F12 medium with 10% foetal bovine serum (FBS). Viability was \>95%. Cell preparations were characterised by FACS analysis using antibodies that distinguish macrophages from other hematopoietic cells. On average, 82.5±3.7% (mean±S.E.M., n=6) of the cells were Mac-1^+^ and F4/80^+^ before plating. The isolated cells were plated and allowed to adhere for 2 h. Non-adherent cells were washed off with PBS, and new culture medium was added. Cells were cultured for 24 h before experimental treatments.

Resident peritoneal exudate cells (PECs) were isolated as described above but without prior elicitation by thioglycollate. For details, see [Supplementary Methods](#SD1){ref-type="supplementary-material"}.

Cell culture {#S14}
------------

MMTV-Neu and MCF-7 cell lines with stable depletion of C/EBPδ were generated by transfection of expression constructs for shRNA against C/EBPδ (or GFP as a control^[@R13]^). Cells were selected in G418 and maintained as pools. ANA-1, RAW 264.7 mouse macrophages and HEK293T cells were cultured in DMEM containing 10% FBS. PPMs and PECs were cultured in DMEM/F12 medium containing 10% FBS. The U-937 human monocytic cell line and elutriated primary human monocytes were cultured in RPMI medium containing 5% FBS. The MMTV-Neu mouse mammary tumour cell line (a kind gift of Dr. William Muller, McGill University) was cultured in DMEM containing 5% FBS and 1X-MEGS (mammary epithelial cell growth supplement). Unless indicated otherwise, LPS was used at 100 ng/ml for 16--24 h.

Peripheral blood-derived monocytes were isolated from healthy donors by counterflow centrifugal elutriation under protocols approved by the Institutional Review Boards of both the National Institute of Allergy and Infectious Diseases and the Department of Transfusion Medicine of the National Institutes of Health after appropriate informed consent.

Transient transfections and RNAi {#S15}
--------------------------------

Cells were transfected by nucleofection using the Amaxa Cell-line Nucleofector Kit V (Cat\# VCA-1003; Lonza AG). A GFP expression construct was included in all transfections to monitor transfection efficiency. The total amount of DNA in each transfection was kept constant by complementation with vector control DNA. All control samples were transfected with vector only. At 24 h post-transfection, cells were treated as indicated. *Cebpd* siRNA oligos were purchased from Dharmacon (\#L-003210-00). Fbxw7-specific siRNAs (Silencer predesigned) with the following sequences were used^[@R13],[@R51]^. *Fbxw7α* RNAi-1: 5'-GGGCAGCAGCGGCGGAGGAdTdT-3' and antisense: 5'-UCCUCCGCCGCUGCUGCCCdTdT-3'. *Fbxw7α* RNAi-2: Sense: 5'- GCACAGAAUUGAUACAACTT-3' and antisense: 5'-GUUAGUAUCAAUUCUGUGCTG-3' *Fbxw7α* RNAi-3: 5'-GUGAAGUUGUUGGAGUAGAdTdT-3' and antisense: 5'-UCUACUCCAACAACUUCACdTdT-3'. *Fbxw7* RNAi-4: Sense: 5'-GCACAGAAUUGAUACAACTT-3' and antisense: 5'-GUUAGUAUCAAUUCUGUGCTG-3'. For silencing Fbxw7α in mouse cells, *Fbxw7α* RNAi-1 (*in vitro* and *in vivo*) and RNAi -2 (*in vivo*) were used. *Fbxw7α* RNAi-3 and *Fbxw7* RNAi-4 were used at a 1:1 ratio in human cells.

Scrambled siRNA (\#D-001960-01-05, Dharmacon) or EGFP siRNA^[@R51]^ (5′-CAAGCTGACCCTGAAGTTC-3′) were used as controls.

For *in vivo* RNAi, mice were injected in the peritoneum with *in vivo*-jetPEI^TM^ (Polyplus) according to the manufacturer's instructions. For details see [Supplementary Methods](#SD1){ref-type="supplementary-material"}.

Western Analysis and In vitro ubiquitination assay {#S16}
--------------------------------------------------

See [Supplementary Methods](#SD1){ref-type="supplementary-material"}

Pulse-Chase Experiment {#S17}
----------------------

RAW264.7 cells were transfected with control or *Fbxw7α* siRNA oligonucleotides. Two days later, the cells were pre-incubated for 30 min in DMEM without methionine and cysteine, pulsed with Tran^35^S-label (ICN; 300 µCi/ml; 1 µCi = 37 kBq) for 20 min, and chased with DMEM/10% FBS plus 20 mM methionine and cysteine for the indicated times. Cells were lysed under denaturing conditions, and proteins were immunoprecipitated with anti-CEBP™ antibody and protein G beads. After SDS-PAGE, the dried gel was processed for phosphorimaging. Signals were quantified by ImageQuant software and plotted using GraphPad Prism 5.

Plasma IL-6 measurement {#S18}
-----------------------

FVB/N mice were injected intraperitoneally with control or *Fbxw7α* siRNA (100 µg) using *in vivo*-jetPEI^TM^ (Polyplus) according to the manufacturer's instructions. Three days later, mice were injected with LPS (40 ng) or vehicle (saline) and euthanised 1 h later to collect heparinised blood. IL-6 was measured in plasma using a mouse IL-6 single analyte ELISA kit according to the manufacturer's instructions (SA Biosciences, Qiagen, USA, \# SEM03015A).

RNA isolation and quantitative real-time PCR {#S19}
--------------------------------------------

RNA was isolated using TRIZOL (Invitrogen), and cDNA was synthesised with Superscript reverse transcriptase III (RT) according to the manufacturer's instructions (Invitrogen, CA). PCR was performed with Taqman gene expression primer/probe sets using the 7500 Fast Real Time PCR instrument (Applied Biosystems). Analysis was performed using the MxPro Software (Stratagene). All reactions were performed in duplicates with "no RT" as the control, and all data are mean±S.E.M. of at least three independent biological replicates. The relative expression levels were measured using the relative quantitation (RQ) ΔΔCt method and normalised to β-actin. The probe sets (Applied Biosystems) were as follows: *Cebpd*: Mm00786711_s1; *Fbxw7a*: Mm01209394_m1; *Tlr4*: Mm00445273_m1; *Il6*: Mm59999064_m1; *Mmp9*: Mm00442991_m1; *Cxcr4*: Mm01292123_m1; *Vegfc*: Mm01202432; *Nos2*: Mm00440502; *Tnfa*: Mm00443258_m1; *Il10*: Mm00439614_m1; *Arg1*: Mm00475988_m1; *Il13*: Mm00434204_m1; *mCsf-1*: Mm00432686_m1; *Egf*; Mm01316968_m1; *Ccl3*; Mm00441259_g1; *Ccl5*: Mm01302427_m1; *Actin*: 4352933-0711018.

Chromatin Immunoprecipitation (ChIP) assay {#S20}
------------------------------------------

ChIP analysis was performed per the manufacturer's instructions (EZ ChIP, \#17--371 RF, Millipore, USA). PPMs at 80--90% confluency were cross-linked, and the chromatin was prepared and sonicated to an average size of 500 bp. The DNA fragments were immunoprecipitated with antibodies specific to C/EBPδ (5 µg; BD69319) or control mouse IgG at 4°C overnight. RAW 264.7 macrophages were nucleofected with control or *Fbxw7* siRNA oligos. Forty-eight hours later, cells were processed as above. After reversal of the cross-linking, the immunoprecipitated chromatin was amplified by PCR as follows: *Tlr4*, 1 cycle of 94°C 3 min, 35 cycles of 94°C 20 sec, 56°C 30 sec, and 72°C 30 sec, and 1 cycle of 72°C 2 min; *Zbrk1*, 1 cycle of 94°C 3 min, 37 cycles of 94°C 20 sec, 56°C 30 sec and 72°C 30 sec, and 1 cycle of 72°C 2 min. *Cebpd*, 1 cycle of 94°C 3 min, 40 cycles of 94°C 20 sec, 56°C 30 sec, and 72°C 30 sec, and 1 cycle of 72°C 2 min. The primers were as follows: Tlr4 proximal: *Tlr4-(S):* 5'-ACAAGACACGGCAACTGATG-3'*Tlr4-(AS):* 5'-GCTTTCATCCCAGGAAGTCA-3'Tlr4 distal: *Tlr4-(S):* 5'-GCCAAGAAGCTCCACAGAG-3'*Tlr4-(AS):* 5'-CATCACTAGTCCAGTCGATACCC-3'Cebpd: *Cebpd- (S):* 5'-TGATCCCTGTTCCGCCTTTGCTAT-3'*Cebpd- (AS):* 5'-AGTGGGTCGGAGACCGGA-3'Zbrk1: *Zbrk1-(S):* 5'-CATTCTCTGGGATACCTACACCTG -3'*Zbrk1(AS):* 5'-CTGTAAAATGGCCGCGCCCATAGC -3'

*In vitro* kinase assay {#S21}
-----------------------

For *in vitro* phosphorylation analysis, C/EBPδ was immunoprecipitated with anti-C/EBPδ antibody from radioimmunoprecipitation assay (RIPA) buffer extracts of HEK293T cells transfected with WT or TTS/AAA C/EBPδ and incubated with 100 ng recombinant GSK-3β in kinase assay buffer, as described previously^[@R52]^. Samples were resolved on SDS-PAGE gels and subjected to autoradiography. The labelled C/EBPδ proteins were digested from the gel with pepsin and analysed by reverse-phase high-performance liquid chromatography (HPLC), phosphoamino acid analysis (PAA) and Edman degradation^[@R52]^.

Luciferase reporter assay {#S22}
-------------------------

RAW 264.7 cells were transfected with TLR4 promoter luciferase reporter constructs^[@R53]^, renilla luciferase expression plasmids along with the indicated expression constructs. To silence C/EBPδ expression, two different short hairpin RNA expression constructs were used at 1:1 ratio, and shRNA against green fluorescent protein (GFP) was used as control^[@R13]^. Forty-eight hours later, luciferase activity was assessed using a luciferase assay kit according to manufacturer's instructions (Promega).

Metabolic Measurements {#S23}
----------------------

Measurements of lactate, glucose, ATP and NO were as described in [Supplementary Methods](#SD1){ref-type="supplementary-material"}.

Statistical analysis {#S24}
--------------------

Unless stated otherwise, quantitative data were analysed by the two-tailed unequal variance t-test and are shown as the mean±S.E.M. The number of samples (n) refers to biological replicates.
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![C/EBPδ promotes HIF-1α expression in macrophages through inhibition of FBXW7α\
**a**) RT-PCR analysis of FBXW7 isoform expression from different sources as follows. 1, primary peritoneal macrophages (PPMs); 2, RAW 264.7 cells; 3, MMTV-Neu mammary tumour tissue; 4, primary mouse embryo fibroblasts. Numbers indicate the position of size markers in base pairs. **(b)** RT-qPCR analysis of *Fbxw7* transcript levels in PPMs from WT and *Cebpd^−/−^* KO mice, cultured +/− LPS (100 ng/ml, 24 h), compared to WT untreated (n=4, \**P*\<0.05; \*\**P*\<0.001). **(c)** Western analysis of nuclear extract (NE) from primary human monocytes nucleofected with siRNA oligos (C, control; D, *CEBPD;* F, *FBXW7*) and treated with LPS (100 ng/ml) and 1%O~2~ (16 h) as indicated. SE, short exposure; LE, long exposure.**(d)** RT-qPCR analysis of *FBXW7* and *CEBPD* transcripts in primary human monocytes as in panel (c) (n=3, \**P*\<0.05; \*\**P*\<0.001). **(e)** Western analysis of NE from PPMs nucelofected with siRNA oligos and treated with LPS (100 ng/ml) and 1%O~2~ for 16 h as indicated. SE, short exposure; LE, long exposure.\
Where applicable, data are mean±S.E.M., evaluated by two-tailed unequal variance t-test.](nihms451081f1){#F1}

![FBXW7α interacts with C/EBPδ and targets it for degradation\
**(a)** RAW 264.7 macrophages were transfected with control or *Fbxw7α* siRNA oligos for 48 h, then pulse-labeled with ^35^S-methionine/cysteine, followed by chased with excess unlabeled aminoacids for the indicated times. Quantitation of the phosphorimage of C/EBPδ signal is depicted in the graph (mean±S.E.M., n=2--3) and representative primary data are shown. **(b)** Western analysis of RAW 264.7 cells transfected with HA-ubiquitin expression constructs and control or *Fbxw7α* siRNA oligos and treated ± MG132 (20 µM, 6 h), followed by immunoprecipitation under denatured conditions with anti-C/EBPδ or IgG (with equal aliquots of the indicated extracts). Input (2.5% of lysate) was analyzed as indicated. **(c)** Alignment of phosphodegron motifs present in known FBXW7 substrates with C/EBPδ and its TTS/AAA mutant. **(d)** Western analysis of RAW 264.7 cells transfected with WT- or TTS/AAA-CEBPδ expression plasmids and/or HA-FBXW7α. **(e)** Western analysis of RAW 264.7 cells transfected with WT or TTS/AAA C/EBPδ expression plasmids and immunoprecipitated with anti-C/EBPδ or IgG and input (2.5% of lysate) as indicated. **(f)** RAW 264.7 cells were transfected with WT- or TTS/AAA-C/EBPδ expression constructs. C/EBPδ was immunoprecipitated and the beads were incubated with FBXW7α and HA-ubiquitin as indicated (see Methods for details) and analyzed by Western with anti-HA and C/EBPδ antibodies. **(g)** Western analysis of RAW 264.7 cells transfected with WT- or TTS/AAA-C/EBPδ, treated ± MG132 (20 µM, 6 h) followed by immunoprecipitation under denatured conditions using anti-C/EBPδ or IgG and input (2.5% of lysate) as indicated. **(h)** Western analysis of RAW 264.7 cells transfected with WT- and TTS/DDD-C/EBP™ for 48 h followed by immunoprecipitation with anti-C/EBPδ or IgG and input (2.5% of lysate) as indicated. **(i)** Western analysis (bottom panel) of RAW 264.7 cells transfected with WT-, TTS/AAA- or TTS/DDD-C/EBPδ expression constructs and treated with CHX as indicated. Quantification (top panel) of the C/EBPδ signal was normalized to actin (n=3, \**P*\<0.05; \*\*\*P\<0.0001; ns, not significant). (**j**) Western analysis of RAW 264.7 cells transfected with WT- or TTS/DDD-C/EBPδ expression constructs and treated ± MG132 (20 µM, 6 h).\
Where applicable, data are mean±S.E.M., evaluated by two-tailed unequal variance t-test.](nihms451081f2){#F2}

![C/EBPδ stability is regulated by GSK-3β phosphorylation\
(**a**) RAW 264.7 cells were transfected with WT or TTS/AAA CEBPδ expression plasmids and treated ± GSK-3β inhibitor CHIR99021 (5 µM, 2 h). Cell extracts were immunoprecipitated with anti-C/EBPδ or IgG (with an aliquot of the indicated extract) and the Western analyzed with anti-phosphothreonine (pT) antibody. (**b**) Western analysis of NE from PPMs (left panel) or RAW 264.7 cells (right panel) treated with GSK-3β inhibitors CHIR99021 or BIO (6-bromoindirubin-3'-oxime) (5 µM, 2 h). β-catenin, which is known to be targeted for degradation by GSK-3β phosphorylation, served as positive control. (**c**) Western analysis of RAW 264.7 cells transfected with WT- or TTS/DDD-C/EBPδ expression plasmids and treated ± GSK-3β inhibitor CHIR99021 for 2 h. (**d**) GSK-3β phosphorylates C/EBPδ *in vitro*. HEK293T cells were transfected with WT- or TTS/AAA-C/EBPδ expression plasmids. C/EBPδ proteins were immunoprecipitated from cell extracts and *in vitro* kinase assay reactions were carried out in the presence or absence of GSK-3β. Samples were resolved by SDS-PAGE and subjected to autoradiography (top panel). Total radioactivity (bottom panel) incorporated into the C/EBPδ protein was quantified (n=3). Representative input levels of C/EBPδ are shown by Western (inset). (**e**) RAW 264.7 cells were treated ± LPS (4 h) and cell extracts were immunoprecipitated with anti-C/EBPδ or IgG antibodies and Western analysis was carried out with anti-phosphothreonine (pT) antibody. Input (2.5% of the lysate) was analyzed as indicated. (**f**) Western analysis (top panel) of RAW 264.7 cells treated ± LPS (100 ng/ml, 4 h) followed by CHX for the indicated times, and quantification of C/EBPδ normalized to β-actin signal (bottom graph) compared to respective untreated (n=3, \**P*\<0.05; \*\**P*\<0.001; \*\*\*\**P* \<0.0001). (**g**) Western analysis of RAW 264.7 cells transfected with HA-GSK-3β-S9A expression plasmids treated ± LPS (4 h) as indicated. (**h**) Western analysis of RAW 264.7 cells pretreated with the PI3K/AKT kinase pathway inhibitor LY294002 (10 µM, 1 h) followed by LPS (100 ng/ml, 4 h) as indicated. Where applicable, data are mean±S.E.M., evaluated by two-tailed unequal variance t-test.](nihms451081f3){#F3}

![FBXW7α suppresses TLR4-mediated LPS responses through C/EBPδ\
(**a**) Western analysis of NE from PPMs transfected with vector or FBXW7α expression constructs and treated with LPS (100 ng/ml, 16 h) as indicated. **(b)** RT-qPCR of the indicated mRNA levels in PPMs nucelofected with FBXW7α expression plasmids and treated with LPS (100 ng/ml, 16 h) as indicated (n=3, \* *P*\<0.05, \*\**P*\<0.001, \*\*\*\**P*\<0.0001). (**c**) Western analysis of PPMs transfected with HA-FBXW7α and treated with LPS (100 ng/ml, 16h) as indicated. SE, short exposure; LE, long exposure. **(d)** Western analysis of proteins from PPMs nucleofected with control or *Fbxw7α* siRNA oligos and treated ± LPS (100 ng/ml, 16 h). The line separates analysis of cytoplasmic (top) and nuclear (bottom) extracts. (e) Western analysis of RAW 264.7 macrophages transfected with siRNA oligos against endogenous *Cebpd* or *Fbxw7α* alone or in combination and treated with LPS (100 ng/ml, 16 h) as indicated. The line separates analysis of cytoplasmic (top) and nuclear (bottom) extracts. **(f)** Western analysis of RAW 264.7 macrophages transfected with the indicated expression plasmids. (**g**) Western analysis of PECs isolated from FVB/N mice 48 h after injection of RNAi against *Fbxw7α*. or control siRNA. (**h**) Plasma IL-6 concentrations from mice injected with RNAi against *Fbxw7α*- or control siRNA for 72 h followed by LPS (40 ng) or vehicle (saline) for 1 h. The horizontal line indicates the median IL-6 concentration (n=4--5, *P* values were determined by the Wilcoxon rank-sum test, *P* \< 0.01). (**i**) Western analysis of PPMs transfected with control or *Fbxw7α* siRNA oligos and treated with LPS (100 ng/ml, 4 h) as indicated. SE, LE; short, long exposure.\
Where applicable, data are mean±S.E.M., evaluated by two-tailed unequal variance t-test (except panel 4h).](nihms451081f4){#F4}

![TLR4 is a direct transcriptional target of C/EBPδ\
(**a**) RT-qPCR analysis of *Tlr4* mRNA levels in WT or *Cebpd* KO PECs and in RAW 264.7 macrophages after *Cebpd* silencing (n=3, \*\*\**P*\<0.001). **(b)** RT-qPCR analysis of *Tlr4* in RAW 264.7 macrophages with or without ectopic FBXW7α (n=3, \*\*\*\*P\<0.0001). **(c)** Schematic of the *Tlr4* promoter with location of putative C/EBP binding sites and of primers used for ChIP. ChIP analysis from PPMs for binding of C/EBPδ to the indicated *Tlr4* promoter regions. IgG and a*Zbrk1* promoter region served as negative controls. Numbers indicate the position of molecular size markers in base pairs. **(d)** Luciferase reporter assay in RAW 264.7 macrophages transfected with the indicated luciferase reporter and shRNA against *Cebpd* (top panel) or FBXW7α expression constructs (bottom panel) (n=3, \**P*\<0.05, \*\**P*\<0.001). ns, not significant. **(e)** Western analysis of PPMs from WT and *Cebpd* KO mice transfected with TLR4 expression plasmids as indicated. **(f)** RT-qPCR analysis of the indicated mRNA levels in PPMs as in panel (e). (n=3, \**P*\<0.05; ns, not significant). **(g)** Western analysis of PPMs from WT and *Cebpd* KO mice treated with 200 ng/ml LPS for the indicated times. Where applicable, data are mean±S.E.M., evaluated by two-tailed unequal variance t-test.](nihms451081f5){#F5}

![*Cebpd null* tumours exhibit reduced expression of TLR4 and altered expression of inflammatory genes\
**(a)** Western analysis of proteins from an MMTV-Neu tumour cell line or MCF-7 cells with stable shRNA-silencing of C/EBP™ expression or control shRNA. The line separates analysis of cytoplasmic (top) and nuclear (bottom) extracts. **(b)** RT-qPCR analysis of *Tlr4* and *Fbxw7* mRNA (left panels) and Western analysis (right panel) of protein from MMTV-Neu tumours of WT and *Cebpd* KO mice (n=5, \**P*\<0.05). **(c,d)** RT-qPCR analysis of mRNA levels of the indicated genes in MMTV-Neu tumour tissue from WT and *Cebpd* KO mice. A.U., arbitrary units. (n=6, \**P*\<0.05; \*\* *P*\<0.001). Where applicable, data are mean±S.E.M., evaluated by two-tailed unequal variance t-test.](nihms451081f6){#F6}

![Schematic describing the feedback loops between TLR4, C/EBPδ and FBXW7α that control LPS signaling\
The shaded boxes indicate the elements of this pathway that were identified in this study.](nihms451081f7){#F7}

###### 

Sites of C/EBPδ phosphorylated by GSK-3β

  ----------------------------------------------------------------------------
  Fractions    Edman\        Peptide                       Phosphoamino acid
               Degradation                                 
  ------------ ------------- ----------------------------- -------------------
  6--7 (P)     4             L.GSTpTPAMY.                  T49

  68--70 (P)   7 (11)        L.AAAAQPpTPPTSPEPPRGSPGPSL.   T156 (S160)
  ----------------------------------------------------------------------------

To identify the phosphorylation sites, labeled WT- and TTS/AAA-C/EBPδ were subjected to in-gel digestion with pepsin (P) followed by HPLC analysis. Edman degradation and phosphoamino acid analysis was performed on the indicated fractions.
